Broadwood Partners reports $6 million acquisition of Insight Molecular Diagnostics shares
IMDX•Broadwood Partners acquired 3,428,571 Insight Molecular Diagnostics common shares at $1.75 each, increasing its direct holdings to 16,113,455 shares.
IMDX•Broadwood Partners acquired 3,428,571 Insight Molecular Diagnostics common shares at $1.75 each, increasing its direct holdings to 16,113,455 shares.
Broadwood Partners acquired 3,428,571 shares of Insight Molecular Diagnostics common stock at $1.75 per share. The transaction increased Broadwood Partners' direct holdings to 16,113,455 shares. Neal C. Bradsher, president of Broadwood Capital, is also listed as a 10% owner in the filing.